This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

ASCP Corner

Second-Generation Antipsychotic-Associated Diabetes Mellitus and Diabetic Ketoacidosis: Mechanisms, Predictors, and Screening Need

Dan Cohen and Christoph U. Correll

Published: May 13, 2009

Article Abstract

Antipsychotic medications, as well as schizophrenia, have beenassociated with an increased risk for diabetes. However, therelative contributions of the underlying illness, unhealthy lifestylebehaviors, and medications used to treat schizophrenia arestill unclear. Although first- and second-generation antipsychoticshave been contrasted broadly in the literature regarding theirrisks for glucoregulatory abnormalities, there is now sufficientevidence to suggest that the risk for diabetes is not uniformwithin each antipsychotic class.

Volume: 70

Quick Links: Metabolic Disorder , Side Effects-Medication

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...